293 related articles for article (PubMed ID: 23357139)
21. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
[TBL] [Abstract][Full Text] [Related]
22. Effects of lipoprotein apheresis on PCSK9 levels.
Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
[TBL] [Abstract][Full Text] [Related]
23. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
[TBL] [Abstract][Full Text] [Related]
24. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
[TBL] [Abstract][Full Text] [Related]
25. Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis.
Heigl F; Hettich R; Mauch E; Klingel R; Fassbender C
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):50-54. PubMed ID: 28160245
[TBL] [Abstract][Full Text] [Related]
26. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F; Grützmacher P; Blume H;
Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
[TBL] [Abstract][Full Text] [Related]
27. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.
Safarova MS; Ezhov MV; Afanasieva OI; Matchin YG; Atanesyan RV; Adamova IY; Utkina EA; Konovalov GA; Pokrovsky SN
Atheroscler Suppl; 2013 Jan; 14(1):93-9. PubMed ID: 23357149
[TBL] [Abstract][Full Text] [Related]
28. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
Klingel R; Heibges A; Fassbender C;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
[TBL] [Abstract][Full Text] [Related]
29. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
Vogt A
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein apheresis--more than just cholesterol reduction?
Neumann CL; Schulz EG; Hagenah GC; Platzer U; Wieland E; Schettler V
Atheroscler Suppl; 2013 Jan; 14(1):29-32. PubMed ID: 23357137
[TBL] [Abstract][Full Text] [Related]
31. The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience.
Sampietro T; Sbrana F; Bigazzi F; Ripoli A; Dal Pino B; Pasanisi EM; Petersen C; Coceani M; Luciani R; Pianelli M
Atheroscler Suppl; 2015 May; 18():268-72. PubMed ID: 25936336
[TBL] [Abstract][Full Text] [Related]
32. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.
Schettler VJ; Neumann CL; Peter C; Zimmermann T; Julius U; Roeseler E; Heigl F;
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):14-20. PubMed ID: 25652812
[TBL] [Abstract][Full Text] [Related]
33. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
Grützmacher P; Öhm B; Szymczak S; Dorbath C; Brzoska M; Kleinert C
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):22-26. PubMed ID: 28233269
[TBL] [Abstract][Full Text] [Related]
34. Lipoprotein (a) and coronary heart disease - is there an efficient secondary prevention?
Mellwig KP; Horstkotte D; van Buuren F
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):18-21. PubMed ID: 28233270
[TBL] [Abstract][Full Text] [Related]
35. Lipoprotein(a)-clinical aspects and future challenges.
Kurt B; Soufi M; Sattler A; Schaefer JR
Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):26-32. PubMed ID: 25732622
[TBL] [Abstract][Full Text] [Related]
36. Lipoprotein apheresis - Shortening of treatment intervals reduces cardiovascular events: Case reports.
Berent T; Berent R; Sinzinger H
Atheroscler Suppl; 2019 Dec; 40():125-130. PubMed ID: 31818444
[TBL] [Abstract][Full Text] [Related]
37. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
[TBL] [Abstract][Full Text] [Related]
38. Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Roeseler E; Julius U; Heigl F; Spitthoever R; Heutling D; Breitenberger P; Leebmann J; Lehmacher W; Kamstrup PR; Nordestgaard BG; Maerz W; Noureen A; Schmidt K; Kronenberg F; Heibges A; Klingel R;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2019-27. PubMed ID: 27417585
[TBL] [Abstract][Full Text] [Related]
39. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a).
Waldmann E; Parhofer KG
Pathology; 2019 Feb; 51(2):227-232. PubMed ID: 30611543
[TBL] [Abstract][Full Text] [Related]
40. Management of lipoprotein-X accumulation in severe cholestasis by semi-selective LDL-apheresis.
Franceschini G; Busnach G; Chiesa G; Sirtori CR
Am J Med; 1991 May; 90(5):633-8. PubMed ID: 2029022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
